Masonic Cancer Center, University of Minnesota
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Masonic Cancer Center, University of Minnesota sits in the top decile of US sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count).
Masonic Cancer Center, University of Minnesota: 249 sponsored US clinical trials, 36 recruiting.
Masonic Cancer Center, University of Minnesota sponsors 249 registered US clinical trials on ClinicalTrials.gov, 36 of them currently recruiting, and 127 completed. 1 of these trials are in Phase 3-4 (later-stage) and 183 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 7 trials.
Top-decile sponsor footprint
Masonic Cancer Center, University of Minnesota ranks in the top decile of sponsors by registered trial count (#132 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
127 of 201 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (63.2%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
249 total, page 5 of 5
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
NCT00357565
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
NCT00622674
Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00331422
Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
NCT00345865
MT2004-30: Tomotherapy for Solid Tumors
NCT00623077
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases
NCT00309842
Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
NCT00258362
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
NCT00618696
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease
NCT00392782
Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant
NCT00305682
Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine
NCT00293293
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
NCT00274846
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
NCT00287911
Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant
NCT00303667
Chemoradiation in Locally Advanced Pancreatic Cancer
NCT00262951
Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites
NCT00265863
Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
NCT00287859
Autologous Transplant for Multiple Myeloma
NCT00177047
Stem Cell Transplant w/Laronidase for Hurler
NCT00176891
Stem Cell Transplantation for Fanconi Anemia
NCT00167206
Post Transplant Donor Lymphocyte Infusion
NCT00167180
Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors
NCT00095160
CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
NCT00369291
Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer
NCT00619021
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
NCT00290654
Stem Cell Transplant for Immunologic or Histiocytic Disorders
NCT00176865
Vaccination With Tetanus and KLH to Assess Immune Responses.
NCT00000105
Stem Cell Transplant for Hemoglobinopathy
NCT00176852
Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer
NCT00281827
Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia
NCT00258427
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
NCT00303719
Stem Cell Transplant for Hematological Malignancy
NCT00176930
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer
NCT00290641
T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders
NCT00176826
Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
NCT00005985
Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma
NCT00005987
Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia
NCT00005986
Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia
NCT00005984
Stem Cell Transplantation for Hematological Malignancies
NCT00176839
Stem Cell Transplant for Bone Marrow Failure Syndromes
NCT00176878
Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia
NCT00630253
Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
NCT00167219
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
NCT00612716
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
NCT00290628
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
NCT00609739
Stem Cell Transplantation for Hurler
NCT00176917
Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors
NCT00003926
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
NCT00167167
Stem Cell Transplant for Inborn Errors of Metabolism
NCT00176904
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 76 |
| Phase 2 | 107 |
| Phase 3 | 1 |
What is open in the Masonic Cancer Center, University of Minnesota pipeline
36 recruiting of 249 indexed (14% open); 127 completed (51%).
Phase mix: 1 late (III/IV) vs 183 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Masonic Cancer Center, University of Minnesota: open-pipeline peers nationwide
Peers matched on 249 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Masonic Cancer Center, University of Minnesota sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 249 trials (± recruiting share)
- University of South Florida · 252 trials · 17% recruiting
- Boston Medical Center · 253 trials · 11% recruiting
- Shire · 245 trials · 0% recruiting
- University of Cincinnati · 245 trials · 14% recruiting
Sponsors near 14% open enrollment (± trial volume)
- ModernaTX · 14% recruiting · 90 trials
- The Cleveland Clinic · 14% recruiting · 688 trials
- University of Wisconsin, Madison · 15% recruiting · 1,039 trials
- Dana-Farber Cancer Institute · 14% recruiting · 781 trials
Related
What to do with this Masonic Cancer Center, University of Minnesota page
249 registered trials is a research-attention snapshot, not an endorsement of Masonic Cancer Center, University of Minnesota or any single study.
- 36 of Masonic Cancer Center, University of Minnesota's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition Masonic Cancer Center, University of Minnesota studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Masonic Cancer Center, University of Minnesota pipeline card: 249 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.